Table 1. Main characteristics of the studies in this meta-analysis.
| Author | Year | Country | Cancer | Case number | No. of B7-H3(+) | Detection method | Cut-off | Source of HR | Outcome measures | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| Xu et al. [6] | 2010 | China | NSCLC | 102 | 71 | IHC | NR | Reported | OS | 15–50 |
| Brunner et al. [13] | 2012 | Austria | Endometrial | 99 | 29 | IHC | IHS ≥ 9 | SC | OS | 57(24–89) |
| Wu et al. [12] | 2006 | China | Gastric | 102 | 60 | IHC | Average positive cell ratio > 20% | Reported | OS | NR |
| Huang et al. [16] | 2016 | China | Cervical | 108 | 78 | IHC | IRS ≥ 3 | Reported | OS | 36–96 |
| Chen et al. [17] | 2015 | China | Oral | 72 | 48 | IHC | NR | SC | OS | NR |
| Xu et al. [18] | 2013 | China | Pancreatic | 45 | 35 | IHC | IRS > 3 | SC | OS | 29.6(8–64) |
| Wang et al. [19] | 2013 | China | Osteosarcoma | 61 | 37 | IHC | IRS > 3 | SC | OS | 60(24–87.60) |
| Wang et al. [20] | 2016 | China | Esophageal | 66 | 44 | IHC | IRS > 3 | Reported | OS | NR |
| Chen et al. [21] | 2015 | China | Esophageal | 174 | 97 | IHC | H-score > 185 | Reported | OS | NR |
| Mao et al. [22] | 2013 | China | Colorectal | 98 | 45 | IHC | Percentage of stained lymphocytes > 20% | SC | OS | NR |
| Martin Loos [23] | 2009 | Germany | Pancreatic | 68 | 28 | IHC | IRS > 3 | SC | OS | 23(2–44) |
| Maeda et al. [24] | 2014 | Japan | Breast | 90 | 52 | IHC | IRS > 3 | Reported | OS/RFS | 67(7.8–90.5) |
| Sun et al. [25] | 2012 | China | Hepatocellular | 240 | 168 | IHC | IRS: 2 and 3 | SC | OS/RFS | 39 (1.5–95.0) |
| Arigami et al. [26] | 2011 | Japan | Gastric | 95 | 48 | qRT-PCR | NR | Reported | OS | 24 (1–74) |
| Zang et al. [15] | 2007 | USA | Prostate | 803 | 746 | IHC | NR | Reported | PFS | 84(63.6–99.6) |
| Zang et al. [10] | 2010 | USA | Ovarian | 93 | 41 | IHC | IHS > 50 | SC | OS | Low stage: 96(7.2–306) High stage: 12(4.8–94.8) |
| Chen et al. [27] | 2014 | China | Pancreatic | 63 | 43 | IHC | Stained tumor cells > 10% | SC | OS | NR |
| Jin et al. [28] | 2015 | China | NSCLC | 110 | 60 | IHC | NR | SC | OS | 6–60 |
| Liu et al. [29] | 2012 | Norway | Prostate | 130 | 70 | IHC | NR | Reported | PFS/RFS | 84(14–279) |
| Mao et al. [30] | 2014 | China | NSCLC | 128 | 89 | IHC | IRS ≥ 2 | Reported | OS | 53.3(40.3–74) |
| Zhou et al. [31] | 2014 | China | Colorectal | 104 | 59 | IHC | NR | SC | OS | NR |
| Boorjian et al. [32] | 2008 | USA | UCB | 318 | 222 | IHC | Stained tumor cells > 10% | Reported | OS/PFS | ≥ 120 |
| Ingebrigtsen et al. [33] | 2014 | Norway | Colorectal | 731 | 637 | IHC | NR | SC | OS/RFS | 116.4(62.4–207.6) |
| Luo et al. [34] | 2017 | China | Lung | 46 | 37 | IHC | Percentage of immunoreactivity > 30% | Reported | OS | NR |
| Song et al. [35] | 2016 | China | Esophageal | 100 | 66 | IHC | Staining score > 3 | Reported | OS/PFS | 36(5.2–96) |
| Fukuda et al. [36] | 2016 | China | RCC | 181 | 90 | ELISA | NR | Reported | OS | 31(3–100) |
| Liu et al. [37] | 2016 | China | Gallbladder | 126 | 84 | IHC | Stained tumor cells > 10% | SC | OS | NR |
| Inamura et al.[38] | 2017 | Japan | Lung | 270 | 86 | IHC | Intensity 1 ≥ 50% or intensity 2 ≥ 10% | Reported | OS | NR |
NSCLC: non-small cell lung cancer; UCB: urothelial carcinoma of the bladder; RCC: renal cell carcinoma; IHC: immunohistochemistry; ELISA: enzyme-linked immunosorbent assay; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; NR: no report; SC: survival curve; IRS: immunoreactivity score; IHS: immunohistochemical score; HR: hazard ratio; qRT-PCR: quantitative real-time fluorescence polymerase chain reaction.